Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

NARecruitingINTERVENTIONAL
Enrollment

1,320

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

March 31, 2035

Study Completion Date

March 31, 2035

Conditions
Circulating Tumor DNARecurrenceColon Cancer Stage II
Interventions
OTHER

ctDNA analysis after surgery

ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.

Trial Locations (29)

Unknown

RECRUITING

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

RECRUITING

Noordwest Ziekenhuisgroep, Alkmaar

RECRUITING

Ziekenhuisgroep Twente, Almelo

RECRUITING

Flevoziekenhuis, Almere Stad

RECRUITING

Meander Medisch Centrum, Amersfoort

RECRUITING

NKI-AVL, Amsterdam

RECRUITING

Rijnstate, Arnhem

RECRUITING

Amphia Ziekenhuis, Breda

RECRUITING

Reinier de Graaf Gasthuis, Delft

RECRUITING

Deventer Ziekenhuis, Deventer

RECRUITING

Albert Schweizer Ziekenhuis, Dordrecht

RECRUITING

Ziekenhuis Gelderse Vallei, Ede

RECRUITING

Admiraal de Ruyter Ziekenhuis, Goes

RECRUITING

Rivas, Gorinchem

RECRUITING

Spaarne Gasthuis, Haarlem

RECRUITING

Ziekenhuis St. Jansdal, Harderwijk

RECRUITING

Maastricht UMC, Maastricht

RECRUITING

Van Weel-Bethesda Ziekenhuis, Middelharnis

RECRUITING

St. Antonius Ziekenhuis, Nieuwegein

RECRUITING

Canisius Wilhelmina Ziekenhuis, Nijmegen

RECRUITING

Bravis Ziekenhuis, Roosendaal

RECRUITING

Ikazia Ziekenhuis, Rotterdam

RECRUITING

Haaglanden MC, The Hague

RECRUITING

Bernhoven, Uden

RECRUITING

Diakonessenhuis, Utrecht

RECRUITING

UMC Utrecht, Utrecht

RECRUITING

Maxima Medisch Centrum, Veldhoven

RECRUITING

VieCuri Medisch Centrum, Venlo

RECRUITING

St. Jans Gasthuis, Weert

Sponsors
All Listed Sponsors
collaborator

Personal Genome Diagnostics

INDUSTRY

collaborator

The Netherlands Cancer Institute

OTHER

lead

UMC Utrecht

OTHER